A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

November 3, 2026 updated by: Eli Lilly and Company

A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
575

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: LillyTrials@Lilly.com

Study Contact Backup

Study Locations

  • Australia
      • Adelaide, Australia, 5000
        • Recruiting
        • Cancer Research SA
        • Principal Investigator:
          • Meena Okera
      • QLD, Australia, 4101
        • Recruiting
        • Icon Cancer Centre South Brisbane
        • Principal Investigator:
          • Jermaine Coward
  • France
      • Lyon, France, 69373
        • Recruiting
        • Centre Leon Berard
        • Principal Investigator:
          • Isabelle Ray-Coquard
        • Contact:
          • Phone Number: +33478782644
      • Saint-Herblain, France, 44805
        • Recruiting
        • Institut de Cancerologie de l'Ouest - site St-Herblain
        • Principal Investigator:
          • Mario Campone
        • Contact:
          • Phone Number: +33 02 40 67 99 00
      • Toulouse, France, 31059
        • Recruiting
        • Oncopole Claudius Regaud
        • Principal Investigator:
          • Carlos Gomez-Roca
  • Italy
      • Milan, Italy, 20141
        • Recruiting
        • Istituto Europeo di Oncologia
        • Principal Investigator:
          • Giuseppe Curigliano
        • Contact:
          • Phone Number: +39 02 5748 9599
      • Milan, Italy, 20159
        • Recruiting
        • Humanitas San Pio X
        • Principal Investigator:
          • Domenica Lorusso
  • Japan
      • Shizuoka, Japan, 411-8777
        • Recruiting
        • Shizuoka Cancer Center
        • Contact:
          • Phone Number: 81120023812
        • Principal Investigator:
          • Haruyasu Murakami
      • Tokyo, Japan, 104-0045
        • Recruiting
        • National Cancer Center Hospital
        • Contact:
          • Phone Number: 81120023812
        • Principal Investigator:
          • Takafumi Koyama
      • Tokyo, Japan, 135-8550
        • Recruiting
        • Cancer Institute Hospital of JFCR
        • Principal Investigator:
          • Shigehisa Kitano
        • Contact:
          • Phone Number: 81120023812
  • South Korea
      • Goyang-si Gyeonggi-do, South Korea, 10408
        • Recruiting
        • National Cancer Center
        • Principal Investigator:
          • Myong Cheol Lim
        • Contact:
          • Phone Number: 82-1588-8110
  • Spain
      • Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitario Vall d'Hebron
        • Contact:
          • Phone Number: +34 932543450
        • Principal Investigator:
          • Roberta Mazzeo
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre
        • Contact:
          • Phone Number: +34 913908922
        • Principal Investigator:
          • Ainhoa Madariaga Urrutia
      • Valencia, Spain, 46010
        • Recruiting
        • Hospital Clinico Universitario de Valencia
        • Principal Investigator:
          • Jose Alejandro Perez Fidalgo
        • Contact:
          • Phone Number: +34 961973527
  • United States
    • Arizona
      • Scottsdale, Arizona, United States, 85258
        • Recruiting
        • HonorHealth
        • Contact:
          • Phone Number: 480-323-1350
        • Principal Investigator:
          • Muhammad Khawaja
    • California
      • La Jolla, California, United States, 92037
        • Recruiting
        • University of California, San Diego (UCSD) - Moores Cancer Center
        • Principal Investigator:
          • Ramez Eskander
        • Contact:
          • Phone Number: 858-657-7000
    • Georgia
      • Atlanta, Georgia, United States, 30308
        • Recruiting
        • Emory University
        • Principal Investigator:
          • Beryl Manning-Geist
    • Michigan
      • Grand Rapids, Michigan, United States, 49546
        • Recruiting
        • South Texas Accelerated Research Therapeutics (START) Midwest
        • Principal Investigator:
          • Nehal Lakhani
        • Contact:
          • Phone Number: 616-389-1652
    • New York
      • Mineola, New York, United States, 11501
        • Recruiting
        • NYU Langone Health - Long Island
        • Principal Investigator:
          • Bhavana Pothuri
      • New York, New York, United States, 10065
        • Recruiting
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • Principal Investigator:
          • Chrisann Kyi
      • New York, New York, United States, 10016
        • Recruiting
        • New York University (NYU) Clinical Cancer Center
        • Principal Investigator:
          • Bhavana Pothuri
        • Contact:
          • Phone Number: 212-731-5100
    • Ohio
      • Columbus, Ohio, United States, 43210
        • Recruiting
        • The Ohio State University (OSU) Wexner Medical Center
        • Principal Investigator:
          • David O'Malley
    • Texas
      • Houston, Texas, United States, 77030-4000
        • Recruiting
        • The University of Texas - MD Anderson Cancer Center
        • Principal Investigator:
          • Shannon Westin
    • Utah
      • West Valley City, Utah, United States, 84119
        • Recruiting
        • START Mountain Region
        • Principal Investigator:
          • William McKean
    • Virginia
      • Falls Church, Virginia, United States, 22042
        • Not yet recruiting
        • Inova Schar Cancer Institute
        • Principal Investigator:
          • Leslie Randall

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Have one of the following solid tumor cancers:

    • Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
    • Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
    • Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer

Exclusion Criteria:

  • Individual with known or suspected uncontrolled central nervous system (CNS) metastases
  • Individual with history of carcinomatous meningitis
  • Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Individual with evidence of corneal keratopathy or history of corneal transplant
  • Any serious unresolved toxicities from prior therapy
  • Significant cardiovascular disease
  • Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
  • History of pneumonitis/interstitial lung disease
  • Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Sofe-M (Dose-escalation, Cohort A1)

Escalating doses of Sofe-M administered intravenously (IV)
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Experimental: Sofe-M (Cohort A1 Parts A and C)

Sofe-M administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Experimental: Sofe-M Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B)

Sofe-M administered IV and itraconazole administered orally
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Drug: Itraconazole

oral
Experimental: Sofe-M (Dose-optimization, Cohort A2)

Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Experimental: Sofe-M (Enrichment Cohort A3)

Monotherapy administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Experimental: Sofe-M (Combination Cohort A4)

Combination with bevacizumab administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Drug: bevacizumab

IV
Experimental: Sofe-M (Combination Cohort A5)

Combination with carboplatin administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Drug: carboplatin

IV
Experimental: Sofe-M Combination with Pembrolizumab (Dose-optimization Cohort A6)

Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with pembrolizumab
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Drug: pembrolizumab

IV
Experimental: Sofe-M Combination with carboplatin and optional bevacizumab (Dose-optimization Cohort A7)

Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with or without bevacizumab
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Drug: bevacizumab

IV

Drug: carboplatin

IV
Experimental: Sofe-M (Dose-expansion, Cohort B2-B4)

Sofe-M administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156
Experimental: Sofe-M (Dose-expansion, Cohort B1)

Sofe-M administered IV
Drug: Sofe-M

Intravenous

Other Names:
  • sofetabart mipitecan
  • LY4170156

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Phase 1a: To determine the recommended phase 2 dose (RP2D) of Sofe-M (LY4170156)
Time Frame: 1 Cycle (21 or 28 days)

Number of participants with dose-limiting toxicities (DLTs)
1 Cycle (21 or 28 days)
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with bevacizumab
Time Frame: 1 Cycle (21 or 28 days)

Number of participants with DLTs
1 Cycle (21 or 28 days)
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with carboplatin
Time Frame: 1 Cycle (21 or 28 days)

Number of participants with DLTs
1 Cycle (21 or 28 days)
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with pembrolizumab
Time Frame: 1 Cycle (21 or 28 days)

Number of participants with DLTs
1 Cycle (21 or 28 days)
Phase 1b: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: Overall response rate (ORR)
Time Frame: Up to Approximately 60 Months or 5 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Up to Approximately 60 Months or 5 Years
Phase 2: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: ORR
Time Frame: Up to Approximately 60 Months or 5 Years

ORR per RECIST 1.1
Up to Approximately 60 Months or 5 Years
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Up to Approximately 60 Months or 5 Years

A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
Up to Approximately 60 Months or 5 Years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
To characterize the pharmacokinetics (PK) properties of Sofe-M (LY4170156): Minimum Plasma Concentration (Cmin)
Time Frame: First 4 Cycles (84 days)

PK: Cmin of Sofe-M (LY4170156)
First 4 Cycles (84 days)
To characterize the PK properties of Sofe-M (LY4170156): Cmin with bevacizumab or carboplatin
Time Frame: First 4 Cycles (Approximately 84 days)

PK: Cmin of Sofe-M (LY4170156)
First 4 Cycles (Approximately 84 days)
To characterize the PK properties of Sofe-M (LY4170156): Cmin with pembrolizumab
Time Frame: First 4 Cycles (84 days)

PK: Cmin of Sofe-M (LY4170156)
First 4 Cycles (84 days)
To characterize the PK properties of Sofe-M (LY4170156): Area under the concentration versus time curve (AUC)
Time Frame: First 4 Cycles (84 days)

PK: AUC of Sofe-M (LY4170156)
First 4 Cycles (84 days)
To characterize the patient-reported outcomes (PRO) Common Terminology Criteria for Adverse Events (CTCAE) of Sofe-M (LY4170156)
Time Frame: Up to Approximately 60 Months or 5 Years

PRO-CTCAE of Sofe-M (LY4170156)
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR)
Time Frame: Up to Approximately 60 Months or 5 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab
Time Frame: Up to Approximately 60 Months or 5 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR)
Time Frame: Up to Approximately 60 Months or 5 Years

DOR per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab
Time Frame: Up to Approximately 60 Months or 5 Years

DOR per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR)
Time Frame: Up to Approximately 60 Months or 5 Years

TTR per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab
Time Frame: Up to Approximately 60 Months or 5 Years

TTR per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS)
Time Frame: Up to Approximately 60 Months or 5 Years

PFS per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab
Time Frame: Up to Approximately 60 Months or 5 Years]

PFS per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years]
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR)
Time Frame: Up to Approximately 60 Months or 5 Years

DCR per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab
Time Frame: Up to Approximately 60 Months or 5 Years

DCR per investigator assessed RECIST 1.1
Up to Approximately 60 Months or 5 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eli Lilly and Company

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 20, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 30, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 1, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 6, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 3, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 18863
  • LOXO-FRA-24001 (Other Identifier: Eli Lilly and Company)
  • 2024-511238-11-00 (Ctis)
  • J5E-OX-JZXA (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings